minimed

Unlocking the power of the MiniMed™ 780G: Transformative insights from > 100k users across EMEA1

Real-world users† demonstrated consistent outcomes across various ages, genders, geographic regions, and initial glycemic levels

	All users	All users Rec settings	< 15 years Rec settings	> 56 years Rec settings
Participants,N	101,629	6,531	1,366	803
GMI, %	7.0	6.7	6.7	6.6



Consistent glycemic control

Users demonstrated consistent achievement of target glycemic control, with a mean Time in Range (TIR) of 72.3% and a significant portion meeting international targets for glucose management indicators and time below range metrics.

Recommended settings yields higher time in range

Users who maintained recommended settings exhibited improved glycemic outcomes, with a TIR of 78.8% and a higher percentage achieving TIR >70%, while safety metrics remained stable.

Large-scale data collection

The study analyzed data from over 100,000 users of the MiniMed™ 780G system across 34 countries in Europe, the Middle East, and Africa (EMEA), providing a comprehensive real-world dataset over three years.

Consistency across demographics

The data showed consistency in glycemic control outcomes across different age groups, genders, geographic regions, and starting glycemia levels, highlighting the system's broad applicability and effectiveness.

Outcomes

The study concluded that over 100,000 users of the MiniMed™ 780G system consistently achieved target glycemic control. The results demonstrate the system's effectiveness and reliability across different age groups and geographic regions, with significant improvements observed in users with recommended settings.

Due to inherent real-world data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

† Number of users with ≥10 days of sensor glucose data.

Analysis of MiniMed™ 780G system data, uploaded into CareLink™ Personal software from August 2020 to August 2023 from 101,629 users (32 countries) further supporting the use of Recommended Settings.[1]

1. Choudhary P., et al. Diabetes Technol Ther. 2024; 26(3): S32-37. doi: 10.1089/dia.2023.0433.

Objective

The study was to benchmark and evaluate the usability and outcomes of the MiniMed™ 780G system among 100,000 users in the Europe, Middle East, and Africa (EMEA) regions. The study aimed to provide insights into the system's effectiveness in managing glucose levels in a real-world setting.

Design

- The study utilized CareLink™ Personal data collected from August 2020 to August 2023.
- The data was analyzed for the full cohort of users and a 12-month longitudinal cohort to assess changes over time.
- Additional analyses were performed for users with optimal settings (those maintaining ≥95% time with a glucose target of 100 mg/dL and ≥95% time with active insulin time of 2 hours). The study also considered different age groups (≤15 and ≥56 years) and various geographic regions.

Outcome parameters

- The average TIR was 72.3%.
- The average GMI was 7%.
- The time below 70 mg/dL (TBR70) was 2.0%, and the time below 54 mg/dL (TBR54) was 0.4%.
- 62.5% achieved a TIR >70%.
- Users with recommended settings showed improved outcomes, with a TIR of 78.8% and 86.3% reaching a TIR >70%.

MiniMed™ 780G insulin pump system

Powered by advanced SmartGuard™ technology

Learn more today

Call 888-882-8602
or visit medtronic.com/hcp/minimed-780g

Access articles online

Important Safety Information for MiniMed™ 780G system with SmartGuard™ technology with Instinct sensor, Simplera Sync™ sensor, and Guardian™ 4 sensor: The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera Sync™ and Guardian™ 4 sensors and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.

WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.

WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g-instinct and the appropriate user guide at https://www.medtronicdiabetes.com/download-library.

Important Safety Information for Extended Infusion Set: The Extended Infusion Set is indicated for up to 7 days of wear for the subcutaneous infusion of insulin from an infusion pump. It is NOT indicated for intravenous (IV) infusion or the infusion of blood or blood products. Inaccurate medication delivery, infection and/or site irritation may result from improper insertion and maintenance of the infusion site. Before insertion, clean the insertion site with isopropyl alcohol. Remove the needle guard before inserting the infusion set. If using this infusion set for the first time, do the first set-up in the presence of your healthcare professional. Do not leave air in the infusion set. Prime completely. Check frequently to make sure the soft cannula remains firmly in place as you may not feel pain if it pulls out. The soft cannula must always be completely inserted to receive the full amount of medication. If the infusion site becomes inflamed, replace the set, and use a new site until the first site has healed. Replace the infusion set if the tape becomes loose, or if the soft cannula becomes fully or partially dislodged from the skin. Regularly replace the infusion set as indicated in the instructions for use, or per the insulin labeling, whichever duration is shorter. For more details, see https://www.medtronicdiabetes.com/important-safety-information.

Accu-Chek and Accu-Chek Guide Link are trademarks of Roche Diabetes Care. For detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events, please consult the device manual. For further information, contact your local Medtronic representative. DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed 780G system algorithm includes technology developed by DreaMed Diabetes.

minimed